SEC Form 4 · accession 0001209191-18-032314
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Burkhard Blank
Officer — Chief Medical Officer
Period of report
May 18, 2018
Accepted (ET)
May 22, 2018 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 18, 2018 | M | 25,000 | $16.50 | A | 58,150 | D | |
| Common StockF1,F2 | May 18, 2018 | S | 25,000 | $23.6635 | D | 33,150 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F3 | $16.50 | May 18, 2018 | M | 25,000 | D | — | May 1, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Exercise and sales pursuant to a 10b5-1 plan.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $23.45 to $24.15 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3The shares subject to this option vest over two years from the May 1, 2017 grant date, with the first 25% having vested at the end of six months after the grant date and the remaining 75% vesting in equal quarterly installments over the remainder of such two year period.